<DOC>
	<DOC>NCT00646386</DOC>
	<brief_summary>Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis</brief_summary>
	<brief_title>Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate to severe PsA Inadequate response to DMARD therapy Corticosteroid stable dose &lt;= 10 mg QD DMARDs must have been taken for 3 months and stable dose for 4 weeks MTX maximum dose = &lt;= 30 mg/week Active chronic plaque PS or documented history of chronic plaque PS No other active skin disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>